Margaret is ARTBIO’s Chief Medical Officer and is responsible for spearheading clinical development and regulatory strategies. Margaret completed her Internal Medicine residency and subsequent Medical Oncology and Hematology fellowship at the University of Utah, where she gained invaluable expertise in the diagnosis, treatment, and management of various cancers. During her fellowship, she focused on advancing her knowledge in both the clinical and research aspects of oncology, honing skills that would later prove essential in her career.

After completing her training, Margaret joined the faculty at the University of Utah and the Huntsman Cancer Institute. In this role, she contributed to the academic community through teaching, mentoring, and conducting clinical and translational research. With a desire to impact the field on a larger scale, Margaret transitioned to the pharmaceutical industry, initially as the Director of Clinical Research at Myriad Pharmaceuticals, then to different roles with increasing responsibilities in the Oncology Therapeutic Area at Johnson & Johnson, where she has leveraged her extensive clinical experience and research expertise to drive innovation in oncology drug development. With over 15 years in the industry, she has played a pivotal role in the development of several oncology therapies that are currently in various stages of clinical trials or already approved for use. Her strategic insights have helped guide drug candidates through the complex phases of research and regulatory approval, ultimately contributing to advancements in cancer care.

Her diverse experience in both academic and pharmaceutical settings has made her a well-rounded leader in oncology drug development, with a deep understanding of the challenges patients face as well as the scientific and regulatory hurdles that must be overcome to bring new treatments to market. In addition to her scientific expertise, Margaret is highly regarded for her collaborative leadership style and her ability to mentor teams across various disciplines, driving cross-functional collaboration to accelerate the development of breakthrough therapies. Margaret remains dedicated to improving the lives of cancer patients through continued innovation in treatment options. When not working, Margaret enjoys reading and spending time outdoors with her family.